Program
trastuzumab deruxtecan
Also written as “Trastuzumab deruxtecan”, “Trastuzumab Deruxtecan” and “DS-8201a”.
Its studies are mostly in Breast Neoplasms · Carcinoma, Non-Small-Cell Lung · Stomach Neoplasms · Neoplasm Metastasis · Endometrial Neoplasms, led by 4 companies.
Drug pageTrastuzumab deruxtecan: every studyAll 120 studies of it, academic ones too, with its approvals, label and forms.Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Daiichi Sankyo | 2611 open or running | phase 3since Apr 13, 2018 | Sep 21, 2015 | Oct 1, 2027phase 3 · NCT05950945 |
| AstraZenecaits history only | 2120 open or running | phase 4since May 21, 2024 | Sep 22, 2017 | Feb 10, 2027phase 2 · NCT06271837 |
| Pfizerits history only | 10 open or running | phase 2since Aug 31, 2020 | Aug 31, 2020 | none ahead |
| Strata Oncologyits history only | 10 open or running | phase 2since Oct 1, 2021 | Oct 1, 2021 | none ahead |
Also a collaborator on its studies: Merck, Parexel, Bristol-Myers Squibb and Gilead Sciences.
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and studies of Daiichi Sankyo only; the figures above count every company.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). An open circle marks the day WHO proposed its name. Dates ahead are the sponsors’ estimates.
Not listed one by one: 13 earlier studies, Sep 21, 2015 to Jul 8, 2019.
- Dec 9, 2016Named trastuzumab deruxtecanINNProposed as its International Nonproprietary Name in WHO's List 116
- Jul 31, 2019Phase 1 study in Breast NeoplasmsNCT04042701 · 115 enrolled · United States, France, Spain and more
- Nov 2, 2020Phase 3 study in HER2-Positive Primary Breast CancerNCT04622319 · 1,600 enrolled · United States, Argentina, Australia and more
- Nov 19, 2020Phase 2 study in Carcinoma, Non-Small-Cell LungNCT04644237 · 152 enrolled · United States, Australia, Canada and more
- Jan 8, 2021Phase 3 study in Stomach NeoplasmsNCT04704934 · 490 enrolled · Argentina, Belgium, Brazil and more
- Jan 19, 2021Phase 2 study in Colorectal NeoplasmsNCT04744831 · 122 enrolled · United States, Australia, Belgium and more
- May 22, 2023Phase 3 study in Breast NeoplasmsNCT05950945 · 250 planned · United States, Australia, Belgium and more
- Dec 8, 2023Phase 3 study in Neoplasm MetastasisNCT06174987 · 75 planned · United States, Australia, Brazil and more
- Dec 9, 2024Phase 3 study in Stomach NeoplasmsNCT06731478 · 726 planned · United States, Argentina, Australia and more
- Feb 5, 2025Phase 3 study in Ovarian NeoplasmsNCT06819007 · 582 planned · United States, Australia, Austria and more
- Mar 21, 2025Phase 3 study in Carcinoma, Non-Small-Cell LungNCT06899126 · 686 planned · United States, Argentina, Belgium and more
- Jun 3, 2025Phase 1 study in RecurrenceNCT07015697 · 76 planned · United States, Brazil, France and more
- Jun 6, 2025Phase 3 study in Endometrial NeoplasmsNCT07022483 · 710 planned · United States, Argentina, Chile and more
- Jun 25, 2026Phase 3 study in Breast NeoplasmsNCT07683754 · 200 planned · United States
- Oct 26, 2026Primary completion moved from 2026-08-03 to 2028-02-17Date moved laterphase 3 · +18 months · NCT06174987
Ahead
- Oct 1, 2027Primary completion: phase 3 study in Breast NeoplasmsNCT05950945
- Feb 17, 2028Primary completion: phase 3 study in Neoplasm MetastasisNCT06174987
- Jun 1, 2028Primary completion: phase 3 study in Stomach NeoplasmsNCT06731478
- Nov 1, 2028Primary completion: phase 3 study in Ovarian NeoplasmsNCT06819007
TargetBeta
“An antibody-drug conjugate (ADC) composed of trastuzumab, a monoclonal antibody targeting human epidermal growth factor receptor 2 (ERBB2; EGFR2; HER2) ”NCIt, by rule
“Receptor protein-tyrosine kinase erbB-2 binding agent”ChEMBL 37, by rule
Other programs on ERBB2
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| Trastuzumabrule | Hoffmann-La Roche | phase 4 | 85 |
| pertuzumabrule | Hoffmann-La Roche | phase 4 | 56 |
| tucatinibrule | Pfizer | phase 4 | 25 |
| disitamab vedotin | RemeGen | phase 3 | 36 |
| trastuzumab rezetecanrule | Jiangsu HengRui Medicine | phase 3 | 36 |
| Lutetium-177 | Novartis | phase 3 | 24 |
| trastuzumab brengitecan | Sichuan Biokin Pharmaceutical | phase 3 | 21 |
| Gallium-68 | Philogen | phase 3 | 17 |
| zongertinibrule | Boehringer Ingelheim | phase 3 | 15 |
| Anti-HER2/Topoisomerase I Inhibitor ADC TQB2102 | Sino Biopharmaceutical | phase 3 | 13 |
| sunvozertinibrule | Dizal Pharmaceuticals | phase 3 | 12 |
| anbenitamab | CSPC Pharmaceutical Group | phase 3 | 12 |
Studies
All 26 Daiichi Sankyo leads, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT07683754Breast Neoplasms · United States | 3 | Recruiting | Jul 4, 2030 | 200 |
| NCT07022483Endometrial Neoplasms · United States, Argentina, Chile and more | 3 | Recruiting | Feb 26, 2030 | 710 |
| NCT07015697Recurrence · United States, Brazil, France and more | 1 | Recruiting | Dec 31, 2028 | 76 |
| NCT06899126Carcinoma, Non-Small-Cell Lung · United States, Argentina, Belgium and more | 3 | Recruiting | Apr 24, 2030 | 686 |
| NCT06819007Ovarian Neoplasms · United States, Australia, Austria and more | 3 | Recruiting | Nov 1, 2028 | 582 |
| NCT06731478Stomach Neoplasms · United States, Argentina, Australia and more | 3 | Recruiting | Jun 1, 2028 | 726 |
| NCT06174987Neoplasm Metastasis · United States, Australia, Brazil and more | 3 | Recruiting | Feb 17, 2028 | 75 |
| NCT05950945Breast Neoplasms · United States, Australia, Belgium and more | 3 | Recruiting | Oct 1, 2027 | 250 |
| NCT04744831Colorectal Neoplasms · United States, Australia, Belgium and more | 2 | Completed | Nov 1, 2022 | 122 |
| NCT04704934Stomach Neoplasms · Argentina, Belgium, Brazil and more | 3 | Active, not recruiting | Aug 31, 2026 | 490 |
| NCT04644237Carcinoma, Non-Small-Cell Lung · United States, Australia, Canada and more | 2 | Completed | Dec 23, 2022 | 152 |
| NCT04622319HER2-Positive Primary Breast Cancer · United States, Argentina, Australia and more | 3 | Active, not recruiting | Jul 2, 2025 | 1,600 |
| NCT04042701Breast Neoplasms · United States, France, Spain and more | 1 | Active, not recruiting | Jul 21, 2025 | 115 |
| NCT04014075Neoplasm Metastasis · United States, Belgium, Italy and more | 2 | Completed | Nov 8, 2021 | 79 |
| NCT03734029Breast Neoplasms · United States, Austria, Belgium and more | 3 | Completed | Jan 11, 2022 | 557 |
| NCT03523572Breast Neoplasms · United States, Belgium, France and more | 1 | Completed | Jul 22, 2021 | 86 |
| NCT03529110Breast Neoplasms · United States, Australia, Belgium and more | 3 | Completed | May 21, 2021 | 524 |
| NCT03523585Breast Neoplasms · United States, Australia, Belgium and more | 3 | Completed | Jun 30, 2022 | 608 |
| NCT03505710Carcinoma, Non-Small-Cell Lung · United States, France, Japan and more | 2 | Terminated | May 3, 2021 | 181 |
| NCT03384940Colorectal Neoplasms · United States, Italy, Japan and more | 2 | Completed | Aug 9, 2019 | 86 |
| NCT03383692Neoplasm Metastasis · Japan, Korea, Republic of, Taiwan | 1 | Completed | Sep 26, 2018 | 40 |
| NCT03368196Adenocarcinoma · Taiwan | 1 | Completed | Sep 14, 2018 | 12 |
| NCT03366428Breast Neoplasms · Japan | 1 | Completed | Dec 5, 2018 | 51 |
| NCT03329690Gastrointestinal Neoplasms · Japan, Korea, Republic of | 2 | Completed | Nov 8, 2019 | 233 |
| NCT03248492Breast Neoplasms · United States, Belgium, Canada and more | 2 | Terminated | Mar 21, 2019 | 253 |
| NCT02564900Neoplasms · United States, Japan | 1 | Completed | Feb 1, 2019 | 292 |
How it is read
Names in the registry
- “Trastuzumab deruxtecan”, 22 entries
- “Trastuzumab Deruxtecan”, 10 entries
- “DS-8201a”, 7 entries
- “Trastuzumab deruxtecan (DS-8201a)”, 3 entries
- “T-DXd”, 2 entries
Conditions, from the studies’ own filings
- Breast Neoplasms, 19 studies
- Carcinoma, Non-Small-Cell Lung, 7 studies
- Stomach Neoplasms, 5 studies
- Neoplasm Metastasis, 4 studies
- Endometrial Neoplasms, 2 studies
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.